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FROM GENOME TO STRUCTURE AND BEYOND
Mariagrazia Pizza, Senior Scientific Director Bacterial Vaccines at GSK, Siena, Italy
mariagrazia.x.pizza@gsk.com

The genomic era has completely changed the vaccinology landscape. Starting from the genomic repertoire of
microbial pathogens it is possible to identify novel antigens expected to induce a potent immunoresponse.
Identified antigens can be expressed in different forms, as recombinant proteins, as fusion proteins, in
multimeric forms on nanoparticles or into outer membrane to resemble their natural conformation. Immune
response induced by the expressed antigens is then analyzed using novel in vitro and in vivo models and
immunogenicity and stability improved by structure-based design. Moreover, to accelerate product development,
an in-depth analysis of the physical-chemical properties of the antigens is applied starting from early
development with the aim to identify the critical attributes to be monitored and controlled during vaccine
production and lifecycle, to ensure safety and efficacy of the vaccine product. It is expected that the availability
of new and powerful technologies, the rational based design of new vaccines from antigen discovery to
formulations, product characterization, immunogenicity in animal models and in humans, registration and
lifecycle plans, and proactive interaction with Regulatory Agencies, will result in a fast-track path. The rapid
evolution in the field and the new learnings may address most of the present and future challenges in vaccine
design and development.
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